Background & Aims In 2017, the World Health Organization (WHO) designated
clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and …

Although susceptibility-guided therapy is frequently recommended for Helicobacter pylori
infection, the evidence available to date supporting this strategy is limited. The aim of the …

Background: Bacterial antibiotic resistance changes over time depending on multiple
factors; therefore, it is essential to monitor the susceptibility trends to reduce the resistance …

Background Treating Helicobacter pylori infection according to antibiotic resistance has
been frequently recommended. However, information on its real effectiveness is scarce. Aim …

The gram-negative bacterium Helicobacter pylori (H. pylori) causes chronic gastritis, gastric
and duodenal ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma …

Helicobacter pylori (H. Pylori) is a leading cause of gastroduodenal disease, including
gastric cancer. H. pylori eradication therapies and their efficacy are summarized. A number …

METHODS: Gastric mucosal biopsies were collected from adult participants with H. pylori
infection during screening. Minimum inhibitory concentrations were determined via agar …

Background The cure rate of standard triple therapy for Helicobacter pylori infection is
unacceptably low. Susceptibility-guided therapies (SGTs) have been proposed as an …

The management of Helicobacter pylori (H. pylori) infection treatment differs from the
common treatment protocol for other infectious diseases. Because culture-or molecular …

Background Helicobacter pylori antibiotic resistance leads to frequent treatment failure.
However, the current US prevalence of H. pylori clarithromycin resistance and treatment …